Hillman Capital Management, Inc.: BIOGEN INC (BIIB): Quarterly 13F Position History
As of Q1 2026, Hillman Capital Management, Inc. reported 29,540 shares of BIOGEN INC (BIIB), worth $5.4M and representing 3.8% of its 13F equity book. Quarter-over-quarter share count change: 976 (-3.2%) . The position first appeared in Q4 2019 and has been disclosed across 26 13F-HR filings in Pactolio's tracked window.
- 29,540Shares Held (Latest Filing)
- $5.4MReported Market Value (Latest Filing)
- 3.8%Portfolio Weight (% of 13F Equity Book)
- 976Quarter-over-Quarter Share Change
- +$45.1KQuarter-over-Quarter Value Change
- 44,025Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 26 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 29,540 | 976 | -3.2% | $5.4M | 3.8% | $183.3 |
| Q4 2025 | 30,516 | 7,838 | -20.4% | $5.4M | 3.4% | $176.0 |
| Q3 2025 | 38,354 | 3,618 | -8.6% | $5.4M | 3.1% | $140.1 |
| Q2 2025 | 41,972 | 2,053 | -4.7% | $5.3M | 2.9% | $125.6 |
| Q1 2025 | 44,025 | +959 | +2.2% | $6.0M | 3.0% | $136.8 |
| Q4 2024 | 43,066 | +7,813 | +22.2% | $6.6M | 2.4% | $152.9 |
| Q3 2024 | 35,253 | 701 | -1.9% | $6.8M | 2.3% | $193.8 |
| Q2 2024 | 35,954 | +162 | +0.5% | $8.3M | 2.9% | $231.8 |
| Q1 2024 | 35,792 | +1,316 | +3.8% | $7.7M | 2.5% | $215.6 |
| Q4 2023 | 34,476 | +170 | +0.5% | $8.9M | 3.1% | $258.8 |
| Q3 2023 | 34,306 | +4,895 | +16.6% | $8.8M | 3.4% | $257.0 |
| Q2 2023 | 29,411 | 125 | -0.4% | $8.4M | 3.0% | $284.9 |
| Q1 2023 | 29,536 | 540 | -1.8% | $8.2M | 3.1% | $278.0 |
| Q4 2022 | 30,076 | 1,678 | -5.3% | $8.3M | 3.3% | $276.9 |
| Q3 2022 | 31,754 | 11,265 | -26.2% | $8.5M | 3.5% | $267.0 |
| Q2 2022 | 43,019 | +340 | +0.8% | $8.8M | 3.2% | $204.0 |
| Q1 2022 | 42,679 | +15,488 | +57.0% | $9.0M | 2.9% | $210.6 |
| Q4 2021 | 27,191 | 1,098 | -3.9% | $6.5M | 2.2% | $239.9 |
| Q3 2021 | 28,289 | +1,050 | +3.9% | $8.0M | 2.8% | $283.0 |
| Q2 2021 | 27,239 | 50 | -0.2% | $9.4M | 3.6% | $346.3 |
| Q1 2021 | 27,289 | +7,360 | +36.9% | $7.6M | 3.3% | $279.7 |
| Q4 2020 | 19,929 | +292 | +1.5% | $4.9M | 2.6% | $244.9 |
| Q3 2020 | 19,637 | +3,391 | +20.9% | $5.6M | 3.9% | $283.7 |
| Q2 2020 | 16,246 | 134 | -0.8% | $4.3M | 3.2% | $267.6 |
| Q1 2020 | 16,380 | 1,734 | -9.6% | $5.2M | 5.0% | $316.4 |
| Q4 2019 | 18,114 | — | — | $5.4M | 3.8% | $296.7 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did Hillman Capital Management, Inc. first disclose a BIIB position in 13F-HR filings?
Hillman Capital Management, Inc. first reported BIOGEN INC (BIIB) on its 13F-HR filing for the period ending 2019-12-31 (Q4 2019). The position has appeared on 26 reported quarters within Pactolio's tracked window.
What was Hillman Capital Management, Inc.'s most recent quarter-over-quarter share-count change in BIIB?
Between Q4 2025 and Q1 2026, Hillman Capital Management, Inc. reduced its BIIB position by 976 shares (-3.2%), leaving 29,540 shares at a market value of $5.4M.
Does the implied price-per-share represent Hillman Capital Management, Inc.'s cost basis in BIIB?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.